Figure 3From: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMean change from baseline to week 24 in quality of life, functional domains, and symptoms assessed by the EORTC QLQ-C30. Note: n = 32 for all scales except the Role Functioning and Cognitive Functioning domain, in which n = 31. EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; QoL, quality of life; SEM, standard error of the mean.Back to article page